Literature DB >> 15192797

The natural history of chronic hepatitis B virus infection.

Brian J McMahon1.   

Abstract

Three stages of chronic hepatitis B virus (HBV) infection are recognized: the immune tolerant phase, the chronic hepatitis B phase, and the inactive hepatitis B carrier phase. Active liver disease is most often found in persons with elevated aminotransferase levels and HBV DNA levels >10(5) copies/mL. Possible risk factors for developing liver disease include older age, male gender, presence of hepatitis B e antigen (HBeAg), HBV genotype, mutations in the precore and core promoter regions of the viral genome, and coinfection with hepatitis D (delta) virus. All persons chronically infected with HBV should be followed every 6 to 12 months with aminotransferase levels. Those with elevated levels should be tested for HBeAg and its antibody (anti-HBe) as well as HBV DNA levels to determine if they are in need of further evaluation with a liver biopsy and are candidates for antiviral therapy. Future research will help clarify the outcome of chronic HBV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15192797     DOI: 10.1055/s-2004-828674

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  43 in total

1.  Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients.

Authors:  Guo-Hong Ge; Yun Ye; Xin-Bei Zhou; Li Chen; Cong He; Dan-Feng Wen; You-Wen Tan
Journal:  World J Gastroenterol       Date:  2015-07-28       Impact factor: 5.742

2.  Death From Liver Disease and Development of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection: A Prospective Study.

Authors:  Myron J Tong; Lawrence M Blatt; Kevin B Tyson; Vincent W C Kao
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

3.  Capacity of a natural strain of woodchuck hepatitis virus, WHVNY, to induce acute infection in naive adult woodchucks.

Authors:  Natalia Freitas; Tetyana Lukash; Megan Dudek; Sam Litwin; Stephan Menne; Severin O Gudima
Journal:  Virus Res       Date:  2015-05-12       Impact factor: 3.303

4.  Management of hepatitis B in developing countries.

Authors:  Zaigham Abbas; Adeel R Siddiqui
Journal:  World J Hepatol       Date:  2011-12-27

5.  Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B.

Authors:  Ruijie Wan; Huimin Liu; Xianbo Wang; Gang Wan; Xiaojing Wang; Guiqin Zhou; Yuyong Jiang; Fengxia Sun; Zhiyun Yang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

6.  Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.

Authors:  Charlie Laohapand; Emvalee Arromdee; Tawesak Tanwandee
Journal:  Hepatol Int       Date:  2015-01-15       Impact factor: 6.047

7.  Clinical Significance of Quantitative HBsAg Titres and its Correlation With HBV DNA Levels in the Natural History of Hepatitis B Virus Infection.

Authors:  Vijay K Karra; Soumya J Chowdhury; Rajesh Ruttala; Sunil K Polipalli; Premashis Kar
Journal:  J Clin Exp Hepatol       Date:  2016-08-03

8.  Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

Authors:  Pham Thi Le Hoa; Nguyen Tien Huy; Le The Thu; Cao Ngoc Nga; Kazuhiko Nakao; Katsumi Eguchi; Nguyen Huu Chi; Bui Huu Hoang; Kenji Hirayama
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

Review 9.  Current treatment indications and strategies in chronic hepatitis B virus infection.

Authors:  George V Papatheodoridis; Spilios Manolakopoulos; Athanasios J Archimandritis
Journal:  World J Gastroenterol       Date:  2008-12-07       Impact factor: 5.742

10.  Characteristics of treatment naïve chronic hepatitis B in Bangladesh: younger populations are more affected; HBeAg-negatives are more advanced.

Authors:  Shanhinul Alam; Nooruddin Ahmad; Golam Mustafa; Khorshed Alam; Mobin Khan
Journal:  Saudi J Gastroenterol       Date:  2008-01       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.